Researchers at the University of Texas Medical Branch at Galveston have successfully harnessed a Zika virus vaccine under development to target and kill the brain cancer known as glioblastoma. The findings are currently available in MBio.
The Zika virus can cause microcephaly, a condition where the fetal brain doesn't fully develop when a pregnant woman is infected with the virus. In contrast, glioblastoma dangerously multiplies brain cells into cancerous tumors. The altered Zika vaccine effectively targeted and destroyed the cancerous brain cells in mice but not healthy cells.
"These findings represent major progress toward developing the Zika vaccine as a safe and effective virotherapeutic treatment for human glioblastoma," said UTMB's Pei-Yong Shi, professor in the department of biochemistry and molecular biology.
Glioblastoma is the deadliest and most common type of brain tumor. Despite surgery, radiation and chemotherapy, glioblastoma has a high rate of return with an average survival of less than two years. The late Sen. John McCain's battle with glioblastoma has drawn into sharp focus how aggressive this form of brain cancer can be.
Glioblastoma is a cancer of the glial cells enmeshed throughout the brain that provide structure, nutrition and oxygen for the nerve cells. The tumor recurrence is likely due to cancerous glioblastoma stem cells that hide in brain tissue close to the tumor mass even after surgery. Microcephaly likely develops because Zika virus targets stem cells in the fetal brain.
These observations led Shi and his colleagues at UTMB and in China to test the safety and effectiveness of UTMB's potential Zika virus vaccine in treating mice that were given human glioblastoma tumors to see if the virus would infect and kill the glioblastoma stem cells without harming normal brain cells. They found that the Zika vaccine caused no neurological symptoms or behavioral abnormalities while significantly reducing tumor growth and prolonging survival.
"The current study takes advantage of our recently developed Zika vaccine candidate," Shi said. "We will continue to improve the therapeutic potential of this platform by increasing the safety and increasing the specific cancer-killing activity. It is exciting to turn the "bad" side of the virus into cancer treatment."
Other authors include UTMB's Chao Shan and Xuping Xie as well as Qi Chen, Jin Wu, Qing Ye, Chunfeng Li, Xiao-Feng Li, Xiaoling Qin, Tongyang Zhao and Cheng-Feng Qin from the Academy of Military Medical Sciences, Beijing, China; Feng Ma and Dapei Li from the Chinese Academy of Medical Sciences & Peking Union Medical College; Qian Zhu, Yan Wu and Haitao Wu from the Beijing Institute of Basic Medical Sciences, China; Xiaoyan Zhan and Jianghong Man from the National Center of Biomedical Analysis, Beijing, China.
Source: University of Texas Medical Branch at Galveston
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.